It was great to catch up with Prof. Jakob Grauslund (Odense University Hospital, Odense, Denmark) to discuss the advantages of navigated laser photocoagulation systems and their advantages over traditional retinal laser for the treatment of diabetic macular oedema and proliferative diabetic retinopathy.
The abstract ‘Navigated laser in DME and PDR?’ was presented at EURETINA 2022, 1–4 September 2022
Disclosure: Jakob Grauslund has served on advisory boards for Bayer, Novartis, Roche and Allergan.
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Lisa Glass.
Filmed as a highlight of EURETINA 2022.
- What are the current unmet needs in the treatment of diabetic macular oedema and proliferative diabetic retinopathy? (00:28)
- Could you tell us a little about navigated laser photocoagulation systems and their advantages, compared with traditional retinal laser? (01:20)
- What clinical evidence supports the use of navigated laser systems? (01:56)
- What is the optimal timing of the use of this therapy? (03:30)
- What questions remain unanswered and what future studies are planned? (04:15)
Disclosure: Jakob Grauslund is on the Advisory Board for Bayer, Novartis, Roche and Allergan
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Lisa Glass.
Filmed as a highlight of EURETINA 2022.
